SUZHOU, China, Feb. 24, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announcedClini...
SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, tha...
* Interim analysis expected in the second quarter of 2022 SUZHOU, China, Jan. 13, 2022 /PRNewswir...
SUZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharma...
SUZHOU, China, Dec. 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced dosi...
SUZHOU, China, Dec. 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharma...
SUZHOU, China, Nov. 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that...
SUZHOU, China, Oct. 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, a p...
SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharm...
* ENREACH-LUNG-01 is a multi-center, randomized, double-blind, placebo-controlled phase III clini...
SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), announced the...
SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced toda...
SUZHOU, China, June 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the ...
SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data ...
* KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical...
* As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in th...